AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06685666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastic band exercises added to the traditional warm-up
Description: The experimental group will be given elastic band exercises for 6 weeks after the static and dynamic exercises in the traditional warm-up and then continue with the warm-up with the ball. The exercise program was planned progressively. The exercises will be done in the first 3 weeks, 2 sets of 10 repetitions with a light resistance band. Then the exercises will be done in 3 sets of 10 repetitions with a medium resistance band. There are 8 band exercises in total.This exercise; Flexion and Extension Exercise in Diagonal Pattern, Internal and external rotation with the arm next to the body and the elbow in 90 degrees flexion, Internal and external rotation with the arm in 90 degrees abduction and the elbow in 90 degrees flexion, Scaption Exercise, Rowing, Biceps and Triceps (elbow flexion and extansion exercise), Wrist Flexors and Extensors (wrist flexion and extansion exercise).
Study NCT05733702 — intervention group
Intervention type: OTHER
Intervention: All participants will be asked to provide data and samples for collection and analysis.
Description: During the first year from the date of inclusion, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at 3 months, and at 12 months. Patient-Reported Outcomes (PROs) with voice recordings will be collected at different time points in-between clinical visits using the Colive application. Participants will be asked to provide biological samples (i.e., blood, dried blood spots and stool are mandatory; saliva, urine and hair are optional), tissue samples from endoscopic biopsy and imaging data (if performed as per standard of care) at three timepoints (baseline; 3 months; 12 months). One unscheduled visit may be included in the study in case of occurrence of flare or treatment change.A long-term follow-up (starting from month 12 and up to 4 years after month 12) will include the collection of medical data on a yearly basis, collection of PROs with voice recording every 6 months and continuous collection of data using the smartwatch.
Study NCT05935644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ORCHID
Description: The intervention includes 8 modules, which are delivered online, approximately 30 minutes per session, and participants will engage a minimum of once per week. Participants may also meet online or in-person with a navigator, up to 4 times.
Study NCT04655092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P1101 (Ropeginterferon alfa-2b)
Description: The subjects who have completed the 52-week treatment duration in Study A19-201 will be treated with P1101, starting at the dose at Week 50. The dose during this study may be increased or decreased up to 500 μg depending on the condition. This study will be continued as a post-marketing clinical study after acquisition of the marketing approval of P1101.
Study NCT05578716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed formula
Description: Partially hydrolysed formula
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirarubicin
Description: pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pirarubicin
Description: pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.
Study NCT05287308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel 80\~100mg/m2, i.v., d1, q3w.
Study NCT05483686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shine
Description: This tailored, multifaceted mobile intervention aims to improve HIV-related outcomes and increase gender affirmation among African American transgender women. Potential users will opt-in by texting from their own mobile phone and, once registered, will be enrolled into a program that will be theory-based, targeted, tailored, and personalized. Users will receive three main types of texts: informational, motivational, and skill-building. Finally, the program will include three web-based video components: scripted vignettes, unscripted peer narratives, and educational instruction. By developing an intervention using a technology that is part of the everyday lives of most African Americans, the aim is to reduce HIV disparities. The proposed intervention can be used by clinics and community-based organizations that serve transgender women.
Study NCT05483686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A playlist of CDC-developed videos designed to provide information on HIV for transgender women
Study NCT02229175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravitreal injections of antibodies inhibiting vascular endothelial growth factor
Study NCT02229175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: intravitreal injections of antibodies inhibiting vascular endothelial growth factor
Study NCT02229175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PASCAL Endpoint Management (EpM) laser treatment
Description: This is an algorithm that is included in the PASCAL 577 mm yellow laser system (Topcon, Santa Clara, CA). This is FDA-approved for treatment of diabetic retinopathy and diabetic macular edema.
Study NCT05847738 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pain assessment
Description: Pain was assesd postoperatively in both groups at time intervals
Study NCT05204862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218
Description: orally administered
Study NCT05204862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Intravenously administered
Study NCT05358678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cs niche group
Description: A niche is formally defined by the European Niche Taskforce as an indentation of the uterine myometrium of at least 2 mm at the site of the CS scars. A niche can be sub classified as follows:~1. Simple niche~2. Simple niche with one branch~3. Complex niche (with more than one branch).~The following measurements will be taken:~* Length.~* Depth.~* Width.~* RMT (residual myometrium thickness).~* AMT (adjacent myometrium thickness).~* Distance between the niche and the VV (vesico-vaginal) fold.~* Distance between the niche and the external os. We will also comment on the position of the uterus (AVF or RVF), presence or absence of intra cavitary fluid and its thickness.
Study NCT04657822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: Concentrate for solution for infusion for Intravenous use
Study NCT06476132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Participants will receive Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
Study NCT06476132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Belumosudil
Description: Participants will receive Placebo for Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
Study NCT05694884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT05694884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN004
Description: ASLAN004
Study NCT06409390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 75 mg/m2 once every 21 days for 4 cycles
Study NCT06409390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 600 mg/m2 once every 21 days for 4 cycles
Study NCT06409390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: 5.4 mg/kg once every 21 days for 5 cycles
Study NCT06409390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles
Study NCT06409390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: 1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles
Study NCT06409390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles
Study NCT06409390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 600 mg orally daily 21 days on, 7 days off
Study NCT06409390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg by mouth twice daily
Study NCT06001502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality distraction therapy
Description: The VR device simulates a 3-dimensional virtual enviroment, seeking to immerse the user in virtual surroundings
Study NCT04954664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allograft particles hydrated with rhPDGF
Description: Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
Study NCT04954664 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allograft particles hydrated in a conventional way with saline.
Description: Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane
Study NCT05199610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aumolertinib
Description: A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.
Study NCT06253390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Metacognitive training
Description: Metacognitive training therapy
Study NCT06253390 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control
Description: management technique as usual
Study NCT06071065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist counselling
Description: Counselling session with Pharmacist about disease and medication therapy.
Study NCT06071065 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist counselling
Description: Counselling session with Pharmacist about disease and medication therapy.
Study NCT00939601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy
Study NCT00939601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Counseling
Study NCT05161208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline 0.6mg/ml) Nasal Spray
Description: Intranasal delivery of OC-01 nasal spray twice daily (BID)
Study NCT05161208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
Study NCT05927025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand K-files
Description: It is used for cleaning and shaping root canals.
Study NCT06318858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplement
Description: Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old
Study NCT06318858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron supplement
Description: Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old
Study NCT05655936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Health Doula Intervention Program
Description: The intervention group will be given a smart blood pressure cuff and a smart scale to monitor weight. The intervention group will receive support provided a postpartum doula until 8-12 weeks postpartum. The doula will provide individualized support during this time, and after 8-12 weeks, women will transition to a doula-moderated support group for the remainder of the study. The intervention group will continue to receive blood pressure and weight monitoring for the remainder of the study.
Study NCT05655936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care includes enrollment into a clinical 6-week home-based blood pressure monitoring program with text messaging support which includes receiving a home blood pressure cuff. Women in the intervention group will be offered the same support as the usual care group, and in addition will receive the intervention and supplies.
Study NCT05655936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care includes enrollment into a clinical 6-week home-based blood pressure monitoring program with text messaging support which includes receiving a home blood pressure cuff. Women in the intervention group will be offered the same support as the usual care group, and in addition will receive the intervention and supplies.
Study NCT05434403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation
Description: vagus nerve electrical stimulation through ear skin
Study NCT05434403 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham vagus nerve stimulation
Description: sham vagus nerve electrical stimulation through ear skin
Study NCT05694988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efferon CT
Description: Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.
Study NCT06296823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated jetlag protocol
Description: 16 hours of wakefulness and an 8 hour scheduled sleep opportunity in a simulated jetlag protocol where you will go to bed and awaken earlier than usual.
Study NCT05973227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of the TRIDENT system
Description: usage of Trident System v1.0, just before the final resection, to obtain some images of the tissue oxygenation.
Study NCT06313047 — intervention group
Intervention type: DRUG
Intervention: Doxorubicin
Description: each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
Study NCT05591248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRR
Description: Eligible patients meeting the inclusion criteria and signed a consent, will have 3x/week the guided rehabilitation session with the VR-tool (with a maximum of 9 VRR-sessions).
Study NCT06290089 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enterotoxigenic E. coli (ETEC) strain
Description: Challenge strain
Study NCT05448547 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy or surgery
Description: see arm/ group description
Study NCT05448547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: initial observation
Description: see arm/ group description
Study NCT05448547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone therapy
Description: androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
Study NCT06178614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-87890387
Description: JNJ-87890387 will be administered.
Study NCT05201781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
Study NCT04750655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin (Topical)
Description: We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
Study NCT04750655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (Topical)
Description: We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
Study NCT06407284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Produce Prescription Group
Description: Participants will receive 16 produce bags, each containing approximately 50 servings of F\&V. The produce bags will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V bags will be distributed to families every 2 weeks for 16 distributions (over approximately 32 weeks). Participants will also receive nutrition education, including MyPlate.gov's Start Simple App for adolescents, and a Virtual Culinary Medicine Program for parents; these nutrition education programs are theory-driven, tailored to diverse populations, and proven to support behavior change.
Study NCT06407284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants in this group will be selected from de-identified Electronic Health Record (EHR) provided by Legacy Community Health with a 1-to-1 match to the intervention group participant's demographic characteristics and Medicaid eligibility.
Study NCT04735016 — intervention group
Intervention type: DEVICE
Intervention: DiamondTemp™ Ablation System
Description: A cardiac ablation will be performed using the DiamondTemp™ Ablation System.
Study NCT04672889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consume 1 sachet per day for 1 months
Study NCT04672889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Babyguard® Breast Milk Probiotics
Description: consume 1 sachet per day for 1 months
Study NCT04970511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBAT (Basic Body Awareness Therapy)
Description: The group I: BBAT Face-to-Face Training (60 min) will be provided.
Study NCT04970511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online BBAT training
Description: The group II: Online BBAT training (60 min) will be provided.
Study NCT06121011 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cipaglucosidase alfa
Description: Enzyme Replacement Therapy (ERT) via intravenous infusion
Study NCT06121011 — intervention group
Intervention type: DRUG
Intervention: Miglustat
Description: Participants received ATB200 co-administered with AT2221 (Miglustat)
Study NCT06121011 — intervention group
Intervention type: BIOLOGICAL
Intervention: Alglucosidase alfa or Avalglucosidase alfa
Description: Patients prescribed other commercially available ERT after local regulatory approval
Study NCT06121011 — intervention group
Intervention type: OTHER
Intervention: Untreated
Description: Patients who are not currently receiving any medical therapy for Pompe disease.
Study NCT04868838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.
Study NCT05755711 — intervention group
Intervention type: DEVICE
Intervention: Shockwave Medical Coronary IVL System
Description: Coronary Intravascular Lithotripsy (IVL)
Study NCT05542498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Training is focused on learning and applying the principles of R.A.I.N. (Recognize, Allow, Investigate, Non-identify) in the context of physics learning.
Study NCT05542498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Training is focused on learning and applying relaxation practices (e.g., progressive muscle relaxation, guided imagery) in the context of physics learning.
Study NCT05029583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine screening
Description: routine screening for advanced NASH
Study NCT05029583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physician-driven screening
Description: physician-driven screening for advanced NASH